For Healthcare Professionals

A Trial of SHR-1701 in Subjects With Advanced Solid Tumors

clipboard-pencil

About the study

This is a dose-escalation and dose-expansion Phase 1 trial to evaluate the safety and tolerability of SHR-1701 in subjects with advanced solid tumors.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Diagnosed (histologically or cytologically) with solid tumors
  2. ECOG Performance Status of 0 or 1 at both the screening and baseline visits
  3. Life expectancy ≥12 weeks
  4. Adequate laboratory parameters
  5. Willing and able to comply with clinic visits and study-related procedures
  6. Provide signed informed consent

EXCLUSION CRITERIA

  1. Known history of hypersensitivity to the study drug
  2. Prior malignancy active within the previous 2 years
  3. Any investigational or concurrent cancer therapy
  4. History of immunodeficiency including seropositivity
  5. Systemic antibiotics treatment for ≥ 7 days before the first dose
  6. A known history of allogeneic organ transplantation
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall +61 02 9299 0433Email iconEmail Study Center

Study’s details


Contition

Advanced Solid Tumor

Age (in years)

18 - 200

Phase

Phase 1

Participants needed

48

Est. Completion Date

Feb 2023

Treatment type

Interventional


Sponsor

Atridia Pty Ltd.

ClinicalTrials.gov identifier

NCT04324814

Study number

SHR-1701-001AUS

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.